BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) has become a therapeutic problem in many parts of the world, necessitating the inclusion of second-line anti-tuberculosis drugs in specific treatment regimens. METHODS: We studied the susceptibility of 69 MDR Mycobacterium tuberculosis isolates from Rwanda to second-line drugs by the BACTEC 460 method. RESULTS: The results showed that 62 (89.9%) were resistant to rifabutin while a low rate (4.3%) of resistance was registered for ofloxacin; there was one case (1.4%) of resistance each for para-aminosalicylic acid, kanamycin, ethionamide, and clarithromycin. CONCLUSIONS: This information is important for devising an appropriate treatment regimen for MDR-TB patients in order to stop the spread of MDR strains and contain the acquisition of additional drug resistance in Rwanda.
BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) has become a therapeutic problem in many parts of the world, necessitating the inclusion of second-line anti-tuberculosis drugs in specific treatment regimens. METHODS: We studied the susceptibility of 69 MDR Mycobacterium tuberculosis isolates from Rwanda to second-line drugs by the BACTEC 460 method. RESULTS: The results showed that 62 (89.9%) were resistant to rifabutin while a low rate (4.3%) of resistance was registered for ofloxacin; there was one case (1.4%) of resistance each for para-aminosalicylic acid, kanamycin, ethionamide, and clarithromycin. CONCLUSIONS: This information is important for devising an appropriate treatment regimen for MDR-TB patients in order to stop the spread of MDR strains and contain the acquisition of additional drug resistance in Rwanda.
Authors: Marilyn C Henderson; Lisbeth K Siddens; Jeffrey T Morré; Sharon K Krueger; David E Williams Journal: Toxicol Appl Pharmacol Date: 2008-10-01 Impact factor: 4.219
Authors: Patrick Orikiriza; Becky Tibenderana; Mark J Siedner; Yolanda Mueller; Frederick Byarugaba; Christopher C Moore; Emily E Evans; Maryline Bonnet; Anne-Laure Page; Joel Bazira; Yap Boum Journal: PLoS One Date: 2015-02-06 Impact factor: 3.240
Authors: Chanda Mulenga; Allan Chonde; Innocent C Bwalya; Nathan Kapata; Mathilda Kakungu-Simpungwe; Sven Docx; Krista Fissette; Isdore Chola Shamputa; Françoise Portaels; Leen Rigouts Journal: Tuberc Res Treat Date: 2010-06-30